Literature DB >> 19651212

Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers.

K Kurz1, T Teerlink, M Sarcletti, G Weiss, R Zangerle, D Fuchs.   

Abstract

OBJECTIVE: Higher concentrations of inflammation and immune activation markers as well as the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) are associated with an increased cardiovascular risk. In vitro, parallel formation of ADMA and macrophage marker neopterin was found in stimulated human peripheral blood mononuclear cells.
METHODS: In 112 HIV-1 infected patients, concentrations of ADMA, SDMA and arginine were compared to C-reactive protein and neopterin concentrations before they were referred to antiretroviral therapy. Disease activity was determined by viral load (qPCR), CD4(+) cell counts (FACS) and neopterin concentrations in plasma and urine (HPLC and ELISA). Additionally, concentrations of lipids were determined.
RESULTS: HIV-1 infected patients presented with increased neopterin, ADMA and SDMA concentrations, whereas CD4(+) counts and arginine and plasma lipid concentrations were low. ADMA and SDMA concentrations significantly correlated with markers of immune activation, but not with plasma lipids.
CONCLUSIONS: Results of this study indicate that increased ADMA and SDMA production may be related to an increased activity of immune activation pathways.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19651212     DOI: 10.1016/j.phrs.2009.07.009

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  14 in total

1.  Comprehensive assessment of the arginine pathway and its relationship to inflammation in HIV.

Authors:  Sahera Dirajlal-Fargo; Khurshid Alam; Abdus Sattar; Manjusha Kulkarni; Nicholas Funderburg; Wai Hong Wilson; Grace A McComsey
Journal:  AIDS       Date:  2017-02-20       Impact factor: 4.177

2.  Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection.

Authors:  Rushi V Parikh; Rebecca Scherzer; Elaine M Nitta; Anna Leone; Sophia Hur; Vanita Mistry; John S Macgregor; Jeffrey N Martin; Steven G Deeks; Peter Ganz; Priscilla Y Hsue
Journal:  AIDS       Date:  2014-02-20       Impact factor: 4.177

3.  Elevated levels of asymmetric dimethylarginine are associated with lower CD4+ count and higher viral load in HIV-infected individuals.

Authors:  Rushi V Parikh; Rebecca Scherzer; Carl Grunfeld; Elaine M Nitta; Anna Leone; Jeffrey N Martin; Steven G Deeks; Peter Ganz; Priscilla Y Hsue
Journal:  Atherosclerosis       Date:  2013-04-30       Impact factor: 5.162

4.  Effect of statin on arginine metabolites in treated HIV-infection.

Authors:  Sahera Dirajlal-Fargo; Vanessa El Kamari; Abdus Sattar; Khurshid Alam; Nicholas Funderburg; Danielle Labbato; Lisa Pirro; Chris T Longenecker; Wai Hong Wilson; Grace A McComsey
Journal:  Atherosclerosis       Date:  2017-09-28       Impact factor: 5.162

5.  High asymmetric dimethylarginine (ADMA) levels in patients with brucellosis.

Authors:  Zafer Mengeloglu; Mahmut Sünnetcioglu; Mehmet Tosun; Abdülkadir Kücükbayrak; Mehmet Resat Ceylan; Ali Irfan Baran; Mustafa Karahocagil; Hayrettin Akdeniz
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

6.  HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction.

Authors:  Jason V Baker; Jacqueline Neuhaus; Daniel Duprez; Matthew Freiberg; Jose I Bernardino; Andrew D Badley; Daniel E Nixon; Jens D Lundgren; Russell P Tracy; James D Neaton
Journal:  J Acquir Immune Defic Syndr       Date:  2012-06-01       Impact factor: 3.731

7.  Cerebral changes occurring in arginase and dimethylarginine dimethylaminohydrolase (DDAH) in a rat model of sleeping sickness.

Authors:  Donia Amrouni; Anne Meiller; Sabine Gautier-Sauvigné; Monique Piraud; Bernard Bouteille; Philippe Vincendeau; Alain Buguet; Raymond Cespuglio
Journal:  PLoS One       Date:  2011-03-09       Impact factor: 3.240

8.  The kynurenine pathway activities in a sub-Saharan HIV/AIDS population.

Authors:  Priyesh Bipath; Peter F Levay; Margaretha Viljoen
Journal:  BMC Infect Dis       Date:  2015-08-19       Impact factor: 3.090

9.  Asymmetric dimethylarginine levels in patients with cutaneous anthrax: a laboratory analysis.

Authors:  Mahmut Sunnetcioglu; Zafer Mengeloglu; Ali Irfan Baran; Mustafa Karahocagil; Mehmet Tosun; Abdulkadir Kucukbayrak; Mehmet Resat Ceylan; Hayrettin Akdeniz; Cenk Aypak
Journal:  Ann Clin Microbiol Antimicrob       Date:  2014-03-26       Impact factor: 3.944

10.  Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.

Authors:  Luis M Beltrán; Rocío Muñoz Hernández; Rebeca S de Pablo Bernal; José S García Morillo; Jesús Egido; Manuel Leal Noval; Sara Ferrando-Martinez; Luis M Blanco-Colio; Miguel Genebat; José R Villar; Rafael Moreno-Luna; Juan Antonio Moreno
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.